NCT01767610已完成1 期
Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Drug-Drug interaction evaluation (Cmax,ss, Cmin,ss, Tmax,ss)
研究概览
简要总结
To evaluate pharmacokinetic drug interaction by comparing the steady-state pharmacokinetic characteristics of each arms after repeated administrating Lipilfen cap. 160mg and Livalo tab. 2mg through 3 period by separately or combinedly.
详细描述
To develop combination product of micronized fenofibrate plus pitavastatin, we would like to evaluate pharmacokinetic drug interaction by comparing the steady-state pharmacokinetic characteristics of each arms after repeated administrating Lipilfen cap. 160mg(micronized fenofibrate 160mg)by Dae Woong Pharma. and Livaro tab. 2mg (pitavastatin Ca 2mg) by Joong Wae Pharm. through 3 period by separately or combinedly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Years 20-55
- •Body weight≥50kg and 18≤BMI≤29kg/m2
排除标准
- •Subject with serious active cardiovascular, respiratory, hepatology, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease
- •Subject with symptoms of acute disease within 28days prior to study medication dosing
- •Subject with known for history which affect on the absorption, distribution, metabolism or excretion of drug
- •Subject with clinically significant active chronic disease
- •Subject with any of the following conditions in laboratory test i. AST(aspartate aminotransferase) or ALT(alanine transferase) > upper normal limit × 1.5 ii. Total bilirubin > upper normal limit × 1.5 iii. renal failure with Creatinine clearance < 50mL/min iv. creatine phosphokinase > upper normal limit × 2
- •Positive test results for hepatitis B virus surface antigen, anti-hepatitis C virus antibody, venereal disease research laboratory test
- •Use of any prescription medication within 14 days prior to study medication dosing
- •Use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing
- •Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug)
- •Subject with known for hypersensitivity reaction to fenofibrate, fenofibric acid or statin
- •gallbladder disease
- •Subject who experiences photo-allergy or photo-toxicity during administrating fibrates or ketoprofen
- •Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
- •Subject who is not albe to taking the institutional standard meal
- •Subject with whole blood donation within 60days, component blood donation within 20days
- •Subjects receiving blood transfusion within 30days prior to study medication dosing
- •Participation in any clinical investigation within 60days prior to study medication dosing
- •Continued excessive use of caffeine (caffeine > five cups/day), alcohol(alcohol>30g/day) and severe heavy smoker(cigarette > 10 cigarettes per day)
- •Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator
研究组 & 干预措施
micronized fenofibrate
Experimental
干预措施: micronized fenofibrate 160mg (Drug)
pitavastatin Ca
Experimental
干预措施: pitavastatin Ca 2mg (Drug)
micronized fenofibrate plus pitavastatin Ca
Experimental
干预措施: micronized fenofibrate 160mg plus pitavastatin Ca 2mg (Drug)
结局指标
主要结局
Drug-Drug interaction evaluation (Cmax,ss, Cmin,ss, Tmax,ss)
时间窗: just before dosing on 1st day and 4th day of each period and 0, 0.25, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48hr on final 5th dosing
次要结局
- Number of participants with adverse events(Participants will be followed for the duration of study medication dosing days and hospital stay, and expected average of 3days and follow-up period for maximum 7 days from the discharge)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male SubjectsHypertensionNCT02397538Boryung Pharmaceutical Co., Ltd50
Unknown
1 期
Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male AdultsHealthyNCT04343547Daewoong Pharmaceutical Co. LTD.34
已完成
1 期
A Multi Doses Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult SubjectsSmoking CessationNCT04857047Boryung Pharmaceutical Co., Ltd27
已完成
1 期
Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501Healthy Male VolunteersNCT03089112Hanmi Pharmaceutical Company Limited30
已完成
1 期
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady StateHealthy SubjectsBioavailabilityPharmacokineticsNCT01121926Labopharm Inc.30